STOP-T1D Low-Dose (ATG)

This study has a planned enrollment period of 4 years and once the enrollment phase has concluded, an additional two years of follow-up visits will be conducted for all participants. Participants enrolled in the first year of the study can expect to complete follow-up visits for approximately four additional years if progression to stage 3 (Type 1 Diabetes Onset) does not occur. Participant follow-up visits after the treatment phase of the study includes general assessments (medical history, physical exam, medications and adverse events) and laboratory assessments to determine current health status and glucose tolerance. This study was terminated early due to lack of enrollment and infeasibility of attaining enrollment goals. Follow-up of enrolled participants continued through study termination, approximately 13 months after the first participant enrolled.